TGF-β-neutralizing single-domain antibodies as modular cancer immunotherapeutics
Kevin A. Henry1, Greg Hussack1, Cathy Collins1, John C. Zwaagstra1, Jamshid Tanha1,2,3, C. Roger MacKenzie1,2
1National Research Council Canada, Ottawa, Canada; 2School of Environmental Sciences, University of Guelph, Guelph, Canada; 3Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
Transforming growth factor beta (TGF-β) is a pleiotrophic cytokine that accumulates in the tumour microenvironment and has immunosuppressive effects on tumour-infliltrating lymphocytes. Inhibition of TGF-β (especially targeted inhibition at tumour sites) is a promising strategy, especially in conjunction with other immunotherapies. Here, we report the isolation and functional characterization of llama VHHs directed against human TGF-β3, including sdAbs that target the site of interaction between the cytokine and its cell-surface type II receptor. We recovered a diverse array of VHHs that bound TGF-β with a wide range of affinities and isoform specificities. As fusions to human IgG1 Fc in multiple orientations, we show that the VHH-Fcs potently neutralized TGF-β in in vitro cellular assays. The VHHs identified here are currently being investigated as targeted cancer immunotherapeutics, as fusions to biomolecules targeting tumour antigens. In this application, the stability and modularity of the single IGHV domain carries important advantages over other types of therapeutics.
Credits: None available.
You must be logged in and own this product in order to